1,068 results on '"Crippa, José A."'
Search Results
2. Cannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission
3. Cardiovascular and kidney diseases are positively associated with neuroinflammation and reduced brain-derived neurotrophic factor in patients with severe COVID-19
4. Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans
5. Antinociceptive action of cannabidiol on thermal sensitivity and post-operative pain in male and female rats
6. Biomarkers in Anxiety Disorders
7. Cannabidiol modulates chronic neuropathic pain aversion behavior by attenuation of neuroinflammation markers and neuronal activity in the corticolimbic circuit in male Wistar rats
8. DNA methylation in regulatory elements of the FKBP5 and NR3C1 gene in mother-child binomials with depression
9. What Can We Learn from Animal Models to Study Schizophrenia?
10. Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes
11. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
12. Cannabidiol enhances the antinociceptive effects of morphine and attenuates opioid-induced tolerance in the chronic constriction injury model
13. Magnetic restricted-access carbon nanotubes for SPME to determine cannabinoids in plasma samples by UHPLC-MS/MS
14. Task-independent acute effects of delta-9-tetrahydrocannabinol on human brain function and its relationship with cannabinoid receptor gene expression: A neuroimaging meta-regression analysis
15. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder
16. Research and Clinical Practice Involving the Use of Cannabis Products, with Emphasis on Cannabidiol: A Narrative Review.
17. Cannabidiol reverses memory impairments and activates components of the Akt/GSK3β pathway in an experimental model of estrogen depletion
18. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli
19. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review
20. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum
21. Endocannabinoid System Attenuates Oxaliplatin-Induced Peripheral Sensory Neuropathy Through the Activation of CB1 Receptors
22. Cortical surface abnormalities are different depending on the stage of schizophrenia: A cross-sectional vertexwise mega-analysis of thickness, area and gyrification
23. Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: Possible role of CB1 and TRPV1 receptors
24. Morphine-induced side effects can be differentially modulated by cannabidiol in male and female rats.
25. Cannabidiol modulates hippocampal genes involved in mitochondrial function, ribosome biogenesis, synapse organization, and chromatin modifications.
26. Cannabidiol modulates contextual fear memory consolidation in animals with experimentally induced type-1 diabetes mellitus.
27. Does the "Entourage Effect" in Cannabinoids Exist? A Narrative Scoping Review.
28. Lack of Acute Agomelatine Effect in a Model of Social Anxiety in Healthy Volunteers: A Double-Blind, Placebo-Controlled Trial.
29. The effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on the recognition of emotions in facial expressions: A systematic review of randomized controlled trials
30. Two-weeks treatment with cannabidiol improves biophysical and behavioral deficits associated with experimental type-1 diabetes
31. In-tube solid-phase microextraction with a dummy molecularly imprinted monolithic capillary coupled to ultra-performance liquid chromatography-tandem mass spectrometry to determine cannabinoids in plasma samples
32. Cannabidiol induces antidepressant and anxiolytic‐like effects in experimental type-1 diabetic animals by multiple sites of action
33. Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias
34. Cannabidiol-induced panicolytic-like effects and fear-induced antinociception impairment: the role of the CB1 receptor in the ventromedial hypothalamus
35. Cannabidiol induces autophagy via ERK1/2 activation in neural cells
36. Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit
37. Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors
38. The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression
39. DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor
40. Pharmacological Interaction Between Cannabidiol and Tramadol on Experimental Diabetic Neuropathic Pain: An Isobolographic Analysis.
41. Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma
42. Uso de canabinoides nos distúrbios do movimento
43. Beyond conventional therapy: cannabinoids as an alternative in parkinson's disease
44. Progression of the COVID-19 pandemic, Brazilian healthcare workers’ emotional burden and the effects on professional fulfillment at the end of the third wave: a longitudinal study
45. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review
46. Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases
47. Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats
48. Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos
49. Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder
50. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.